Options of improvement of efficacy of gastroesophageal reflux disease treatment by dioctaedric smectite
Abstract
Aim of investigation. To analyze efficacy of heartburn relief and pathological gastroesophageal reflux (GER) elimination as well as dynamics of endoscopic changes at gastroesophageal reflux disease (GERD) under dioctaedric smectite (Smecta) treatment in standard doze as monotherapy and within complex mode of treatment.
Material and methods. Overall 45 case records of GERD patients (25 women and 20 men, mean age 43,06 years) were analyzed. All patients underwent esophagogastroduodenoscopy (EGDS) and 24-hour рН-impedance recording prior to the treatment onset and at the 14-th day of therapy. The first group included patients with erosive esophagitis (EE) of the I–II degree receiving combination of proton pump inhibitors (PPI) and Smecta, the second group included patients with EE, receiving PPI monotherapy, the third group — patients with non-erosive reflux disease (NERD) at Smecta monotherapy.
Results. On a background of treatment by PPI + Smecta relief of heartburn was achieved at the 3rd day in 10 (66,7%) patients, at PPI monotherapy — in 4 (26,7%) patients with EE, at monotherapy by Smecta — in 6 (40%) patients. At the 5th day heartburn has been completely relieved in 11 (73,3%), 9 (60%) and 8 (53,3%), and at the 14-th day — in 13 (86,7%), 11 (73,3%) and 12 (80%) patients respectively. In the first group according to upper endoscopy data healing of erosions was confirmed in 13 (86,7%) patients, in the second — in 10 (66,7%). In the third group cessation of catarrhal signs was revealed in 13 (86,7%) patients. According to 24-hour рН-impedance esophageal recording prior at the beginning of therapy pathological acidic, weakly acidic and weakly alkalinic GERs were diagnosed in 34 (75,5%), 18 (40%) and 12 (26,7%) patients in group as a whole respectively. On a background of therapy by PPI + Smecta acidic refluxes have been eliminated in 14 (93%), at PPI monotherapy — in 11 (73%), at Smecta monotherapy — in 100% of patients. In the first group weakly acidic refluxes disappeared in 2 (67%), in the second — in 1 (50%), in the third – in 9 (69%) cases, weakly alkaline refluxes: in 4 (80%), in 2 (40%) and in 100% of cases respectively.
Conclusions. Addition of Smecta in treatment mode at erosive form of GERD essentially increases treatment response rate, significantly reducing terms of clinical improvement onset. Dioctaedric smectite appears an effective drug as monotherapy of NERD. The chief advantage in treatment of GERD is ability of the drug to stop all reflux types: acidic, weakly acidic, and weakly alkalinic.
About the Authors
O. A. Storonova
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university»
Russian Federation
Russian Federation
Storonova Olga A. — MD, doctor of functional diagnostics department, Vasilenko Clinic of internal diseases propedeutics, gastroenterology and hepatology
119991, Moscow, Pogodinskaya street, 1, bld 1
A. S. Trukhmanov
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university»
Russian Federation
Russian Federation
Trukhmanov Alexander S. — MD, PhD, professor, Chair of internal diseases propedeutics, medical faculty
N. Yu. Ivashkina
Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Ivashkina Natalya Yu. — MD, PhD, lecturer, Chair of internal diseases propedeutics and gastroenterology
127473, Moscow, Delegatskaya street, 20, bld. 1
V. T. Ivashkin
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university»
Russian Federation
Russian Federation
Ivashkin Vladimir T. — MD, PhD, professor, academician of the Russian Academy of Science, head of the chair of internal diseases propedeutics, medical faculty, director of Vasilenko Clinic of internal diseases propedeutics, gastroenterology and hepatology
References
1. Babayan M.L. Application of Smecta in treatment of gastro-intestinal diseases. Detskaya gastroenterol nutritsiol 2004; 12(16):972-6.
2. Ivashkin V.T., Mayev I.V., Trukhmanov A.S. Barret's esophagus. 2 vol. set. M.: Publishing house «Shiko», 2011. 608 p. and 624 p.
3. Ivashkin V.T., Mayev I.V., Trukhmanov A.S. Instrumental methods and interventions in gastroenterology: manual. M.: GEOTAR-Media, 2015.560 p.
4. Ivashkin V.T., Mayev I.V., Trukhmanov A.S., Baranskaya Ye.K., Dronova O.B., Zayratyants O.V., Pasechnikov V.D., Sayfutdinov R.G., Sheptulin A.A., Kucheryavy Yu.A., Lapina T.L., Storonova O.A., Kaybysheva V.O. Gastroesophageal reflux disease: clinical guidelines. Russian gastroenterological association. М., 2014. 23 p.
5. Ivashkin V.T., Trukhmanov A.S. Modern approach gastroesophageal reflux disease treatment in medical practice. Rus med zhurn 2003; 11(2):43-8. 6. Ivashkin V.T., Trukhmanov A.S. Cholinergic stimulation: its role in realization of motor function of the esophagus and clearance at gastroesophageal reflux disease. Klin perspektivy gastroenterol gepatol 2011; 4:3-8.
6. Kaybysheva V.O. Response of the esophagus to acidic and alkaline refluxes in patients with GERD: Author's abstract. MD degree thesis. М., 2015. 26 p
7. Kaybysheva V.O., Storonova O.A., Trukhmanov A.S., Ivashkin V.T. Potential of intraesophageal рН-impedance recording in diagnostics of GERD. Ros zhurn gastroenterol gepatol koloproktol 2013; 23(2):4-16.
8. Kaybysheva V.O., Trukhmanov A.S., Ivashkin V.T. Proton pump inhibitors-resistant gastroesophageal reflux disease. Ros zhurn gastroenterol gepatol koloproktol 2011; 21(4):4-13.
9. Kaybysheva V.O., Trukhmanov A.S., Storonova O.A., Ivashkin V.T. Scores of рН-impedance measurement at healthy patients. Ros zhurn gastroenterol gepatol koloproktol 2014; 24(5) (suppl. 44):133
10. Mayev I.V., Gulenchenko J.S., Andreyev D.N., Kazyulin A.N., Dicheva D.T. Duodenogastroesophageal reflux: clinical role and approaches to treatment. Consilium Medicum 2014; 08:5-8.
11. Storonova O.A., Trukhmanov A.S. Technique of esophageal motility investigation / ed. V.T. Ivashkin: Manual for postgraduate education. M.: Medpraktika-M, 2011. 34 p.
12. Storonova O.A., Trukhmanov A.S., Dzhakhaya N.L., Ivashkin V.T. Disorders of esophageal clearance at gastroesophageal reflux disease and option of their treatment. Ros zhurn gastroenterol gepatol koloproktol 2012; 22(2):14-21.
13. Storonova O.A., Trukhmanov A.S., Ivashkin V.T. Are pH-metry and investigation of esophageal motor function required for diagnosis and choice of treatment today? Ros zhurn gastroenterol gepatol koloproktol 2010; 20(2):73- 83.
14. Storonova O.A., Trukhmanov A.S., Ivashkin V.T. Role of protective factors of esophageal mucosa in treatment of gastroesophageal reflux disease. Klin perspektivy gastroenterol gepatol 2014; 5:37-42.
15. Trukhmanov A.S. Gastroesophageal reflux disease: clinical variants, prognosis and treatment: Author's abstract. PhD degree thesis. М., 2008.41 p.
16. Trukhmanov A.S., Dzhakhaya N.L., Kaybysheva V.O., Storonova O.A. New aspects of gastroesophageal reflux disease treatment guidelines. Gastroenterology and hepatology. News, opinions, training (Suppl.) 2013; 1(4):2-9.
17. Trukhmanov A.S., Kaybysheva V.O. рН-impedance measurement / ed. V.T. Ivashkin: Manual for doctors. M.: Medpraktika-M, 2013.31 p.
18. Trukhmanov A.S., Storonova O.A., Ivashkin V.T. Clinical impact of investigation of the gut motor function: past, present and future. Ros zhurn gastroenterol gepatol koloproktol 2013; 23 (5): 4-14.
19. Bredenoord A.J. Impedance-pH monitoring: new standard for measuring gastroesophageal reflux. Neurogastroenterol Motil 2008; 20(5):434-9.
20. Bredenoord A.J., Tutuian R., Smout A.J., Castell D.O. Technology review: Esophageal impedance monitoring. Am J Gastroenterol 2007;102(1):187-94. 22. Bredenoord A.J., Weusten B.L., Timmer R., Conchillo J.M., Smout A.J. Addition of esophageal impedance monitoring to pH monitoring increases the yield of symptom association analysis in patients off PPI therapy. Am J Gastroenterol 2006; 101(3):453-9. 23. Kahrilas P.J. Gastroesophageal reflux disease and its complications. In: Feldman M., ed. Sleisenger and Fordtran’s gastrointestinal and liver disease. 6th ed. Philadelphia: WB Saunders Company, 1998:498-516. 24. Kaibysheva V., Trukhmanov A., Ponomarev A., Storonova O., Konkov M., Ivashkin V. Role of acid and nonacid reflux in esophageal mucosal damage (erosive esophagitis and Barrett,s esophagus). United Eur Gastroenterol J 2014; 2 (Suppl. 1):263, P0472.
21. Kao C.H., Ho Y.J., ChangLai S.P., Liao K.K. Evidence for decreased salivary function in patients with reflux esophagitis. Digestion 1999; 60(3):191-5.
22. Leonard A., Droy-Lefaix M., Allen A. Pepsin hydrolysis of the adherent mucus barrier and subsequent gastric mucosal damage in the rat: effect of diosmectite and 16,16 dimethyl prostaglandin e2. Gastroenterocol Clin Biol 1994; 18(6-7):609-16.
23. Lin J.K., Hu P.J., Li C.J., et al. The role of 24-hour esophageal pH and bilirubin monitoring in the diagnosis of duodeno gastroesophageal reflux. Chin J Dig 2001; 21:602-4.
24. Luyer B.Le., Fieffe S., Ducastelle T., Roux P.Le. The value of smectite in the treatment of esophagitis in infants. Extract Ann Pediatr 1987; 34(7):577-81.
25. Mainie I., Tutuian R., Shay S., Vela M., Zhang X., Sifrim D., Castell D.O. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006; 55(10):1398-402.
26. Nehra D. Composition of the refluxate. In: Barrett’s esophagus. John Libbey Eurotext, 2003; 1:18-22.
27. Nehra D., Howell P., Williams C.P., Pye J.K., Beynon J. Toxic bile acids in gastroesophageal reflux disease: influence of gastric acidity. Gut 1999; 44(5):598- 602. 32. Pace F., Sangaletti O., Pallotta S., et al. Biliary reflux and non-acid reflux are two distinct phenomena: a comparison between 24-hour multichannel intraesophageal impedance and bilirubin monitoring. Scand J Gastroenterol 2007; 42:1031.
28. Sifrim D., Castell D., Dent J., Kahrilas P.J. Gastroesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut 2004; 53:1024-31.
29. Tack J., Koek G., Demedts I., Sifrim D., Janssens J. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett’s esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol 2004; 99(6):981-8.
30. Tutuian R., Castell D.O. Review article: complete gastroesophageal reflux monitoring - combined pH and impedance. Aliment Pharmacol Ther 2006; 24 (Suppl. 2):27-37.
31. Vaezi M.F., Richter J.E. Review Duodenogastroesophageal reflux and methods to monitor nonacidic reflux. Am J Med 2001; 3(111) (Suppl. 8A):160-8.
32. Vatier J., Olivier J.F., Vitre M.T., Papazian A. Influence of pH in the adsorption capacity of bile salts and lyso-lecithins in vitro by antacids containing clay and/or aluminum. Gastroenterol clin biol 1989; 13(5):445-51.
33. Xiao-rong Xu, Zhao-shen Li, Duo-wu Zou, Guoming Xu, Ping Ye, Zhen-xing Sun, Qing Wang, Yanjun Zeng. Role of duodenogastroesophageal reflux in the pathogenesis of esophageal mucosal injury and gastroesophageal reflux symptoms. Canad J Gastroenterol 2006; 20(2):91-4.
34. Zerbib F., des Varannes S.B., Roman S., et al. Normal values and day-to-day variability of 24-h ambulatory esophageal impedance-pH monitoring in a Belgian French cohort of healthy subjects. Aliment Pharmacol Ther 2005; 22:1011-32.
35. Zhang J., Yang Z.X. Role of acid reflux and bile reflux in the gastroesophageal reflux disease. J Gastroenterol 2000; 5:207-10.
Review
For citations:
Storonova O.A., Trukhmanov A.S., Ivashkina N.Yu., Ivashkin V.T. Options of improvement of efficacy of gastroesophageal reflux disease treatment by dioctaedric smectite. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;25(5):16-24. (In Russ.)
Views:
853
Email this article 
